查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1806194

感染疾病診斷市場按產品類型、樣本類型、檢測類型、病原體類型、疾病類型和最終用戶分類 - 全球預測 2025-2030

Infectious Disease Diagnostic Market by Product, Sample Type, Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年感染疾病診斷市值將達240.7億美元，2025年成長至261.3億美元，複合年成長率為8.82%，到2030年將達到400億美元。

主要市場統計數據
基準年2024年 240.7億美元
預計2025年 261.3億美元
預測年份 2030 400億美元
複合年成長率（%） 8.82%

揭示影響現代感染疾病檢測的關鍵促進因素和創新

感染疾病診斷領域正處於關鍵的十字路口，臨床對更快、更準確結果的需求日益成長，而儀器和軟體整合的技術突破也不斷湧現。實驗室和即時診斷 (POC)整體面臨快速病原體檢測的壓力，同時也要維持嚴格的敏感度和特異性標準。在此背景下，從醫院網路到學術研究機構，醫療保健領域的相關人員必須調整其營運模式，以充分利用下一代工具和工作流程。

自動化、數據分析和分散式檢查模型如何徹底改變病原體檢測和臨床決策途徑

自動化、高通量能力和數據分析的結合正在重塑感染疾病診斷領域，使實驗室能夠以前所未有的規模處理檢體。與質譜和次世代定序相容的尖端檢測方法與免疫測量和PCR技術相輔相成，能夠以極快的周轉時間對細菌、病毒、真菌和寄生蟲病原體進行多重檢測。

克服新的貿易壁壘和策略採購調整，以在不斷變化的關稅制度下維持診斷測試業務

2025年全年實施的關稅政策增加了用於傳染病檢查的進口試劑、設備和關鍵零件的成本。許多診斷實驗室從疫區購買的抗原檢測套件和免疫檢測分析儀的成本上漲，迫使採購團隊尋找其他國內供應商或調整檢測量以緩解預算限制。

整合產品、檢體、測試、病原體、疾病和最終用戶的觀點，定義客製化的診斷途徑

有效的細分方法可以揭示產品類型之間的微妙促進因素，並揭示儀器、套件和試劑盒以及軟體解決方案的清晰採用模式。在儀器中，免疫檢測分析儀滿足了常規篩檢的臨床需求，而質譜儀和微陣列則滿足了專門的研究應用。 PCR 系統在中心實驗室和照護現場中都越來越受歡迎。試劑和套件用途廣泛：抗原檢測在快速檢測場景中表現出色，ELISA 和免疫測量套件支持高通量工作流程，而 PCR套件則為分子診斷提供了無與倫比的靈敏度。

檢驗區域醫療保健基礎設施和影響全球診斷創新和採用模式的政策促進因素

在美洲地區，成熟的醫療基礎設施和強大的報銷框架持續支持先進診斷平台的採用。在北美，由參考實驗室和學術研究中心組成的網路正在引領新型檢測方法的檢驗；而在拉丁美洲，不斷擴展的公共衛生計畫正在推動對經濟高效、快速檢測方法的需求。經濟多元化和政府對分子診斷技術的投入正在增強大規模篩檢計畫的能力。

探索策略合作夥伴關係和平台整合，以推動更快的檢測開發和可擴展的診斷解決方案

聚焦推動診斷卓越發展的關鍵創新者和策略夥伴關係

一群知名儀器製造商和新興試劑開發人員正在攜手合作，加速將研究級檢測轉化為臨床應用。微陣列供應商與軟體公司之間的合作實現了無縫的數據解讀流程，而套件製造商與參考實驗室之間的合作則確保了在各種臨床條件下進行嚴格的性能檢驗。

建立彈性製造、數據主導洞察和協力網路，以加速診斷敏捷性和市場回應

高階主管應優先考慮實現製造地多元化，以緩解供應鏈脆弱性，並降低貿易政策波動帶來的風險。採用關鍵試劑和設備的彈性生產模式，使企業能夠根據當地疫情情況快速擴大產量。此外，投資模組化、軟體主導的平台，有助於無縫整合新的檢測化學方法，從而加快新興病原體靶點的上市時間。

嚴格的資料收集、專家訪談和詳細的分類框架確保客觀且可操作的市場分析

我們的分析整合了對診斷實驗室、套件製造商、軟體開發商和醫療政策制定者高管進行深入訪談所獲得的主要見解。二次研究則利用同儕審查期刊、監理備案文件和公共衛生機構報告，以檢驗科技採用趨勢和區域部署模式。我們應用了專有框架來繪製產品和疾病分類，以確保儀器、試劑、樣本類型和最終用戶細分的一致性。

自適應技術和協作策略在塑造未來感染疾病檢測中的作用日益增強

隨著全球醫療生態系統持續面臨新興感染疾病的威脅，快速檢測和鑑定病原體的能力仍然是有效應對策略的核心。檢測方法的技術進步，加上強大的軟體整合和分散式檢查能力，正在重新定義診斷工作流程，並實現主動的患者管理。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 對快速診斷以便早期發現感染疾病的需求日益增加
  • 實施人工智慧預測分析，最佳化疫情監測與因應策略
  • 機場和公共設施對快速抗原檢測的需求增加將改善社區安全
  • 擴大照護現場多重檢測，提高分散式傳染病檢查的可及性
  • 基於 CRISPR 的診斷技術的整合簡化了快速病原體檢測工作流程。
  • 拓展遠端醫療協作診療平台，加速遠距感染疾病管理
  • 次世代定序的進步使得臨床實驗室能夠全面鑑定病原體
  • 轉向家用分子檢測套組，以病人為中心的感染疾病監測
  • 基因組工具助力感染追蹤新時代
  • 利用數位生物標記和穿戴式感測器在症狀出現之前預測感染的發生

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章感染疾病診斷市場（按產品）

  • 裝置
    • 免疫檢測分析儀
    • 質譜儀
    • 微陣列
    • PCR體系
  • 試劑和套件
    • 抗原檢測試劑套件
    • ELISA套件
    • 免疫檢測套件
    • PCR套件
  • 軟體

第9章感染疾病診斷市場（依樣本類型）

  • 血
    • 電漿
    • 血清
    • 全血
  • 航班
  • 拭子
    • 鼻腔
    • 直腸
    • 喉
  • 尿

第 10 章感染疾病診斷市場（依測試類型）

  • 實驗室檢查
  • PoC 測試

第11章感染疾病診斷市場（依病原體類型）

  • 細菌
  • 真菌
  • 寄生蟲
  • 病毒
    • 肝炎
    • HIV
    • 流感

第12章感染疾病診斷市場（依疾病類型）

  • 細菌感染疾病
    • 腦膜炎
    • 肺炎
    • 結核
  • 黴菌感染疾病
    • 麴菌症
    • 念珠菌症
    • 隱球菌病
  • 寄生蟲感染疾病
    • 利什曼原蟲症
    • 瘧疾
    • 血吸蟲病
  • 媒介性行為感染感染
    • 登革熱
    • 萊姆病
    • 茲卡病毒
  • 病毒感染疾病
    • 肝炎（甲型、乙型、丙型）
    • 愛滋病毒/愛滋病
    • 流感

第13章感染疾病診斷市場（依最終用戶）

  • 學術研究機構
  • 診斷實驗室
  • 醫院和診所

14.美洲感染疾病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲感染疾病診斷市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16.亞太感染疾病診斷市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Adaptive Biotechnologies Corporation
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • Bio-Techne Corporation
    • bioMerieux SA
    • Boston Scientific Corporation
    • Bruker Corporation
    • Cardinal Health Inc.
    • Cook Medical Incorporated
    • Danaher Corporation
    • GE HealthCare Technologies Inc.
    • Grifols, SA
    • Hologic Inc.
    • Illumina, Inc.
    • Johnson & Johnson Services Inc.
    • Konica Minolta, Inc.
    • Koninklijke Philips NV
    • MedMira Inc.
    • Medtronic PLC
    • Merck KGaA
    • Olympus Corporation
    • Perkin Elmer, Inc.
    • Pfizer Inc.
    • Qiagen NV
    • Quest Diagnostics Incorporated
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Thermo Fisher Scientific, Inc.
    • Trivitron Healthcare

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-4316E4E89510

The Infectious Disease Diagnostic Market was valued at USD 24.07 billion in 2024 and is projected to grow to USD 26.13 billion in 2025, with a CAGR of 8.82%, reaching USD 40.00 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 24.07 billion
Estimated Year [2025] USD 26.13 billion
Forecast Year [2030] USD 40.00 billion
CAGR (%) 8.82%

Unveiling Critical Drivers and Technological Innovations Shaping Modern Infectious Disease Detection

The infectious disease diagnostics arena stands at a pivotal juncture, where technological breakthroughs in instrumentation and software integration converge with rising clinical demands for faster, more precise results. Laboratories and point-of-care settings alike are under increasing pressure to deliver rapid pathogen detection while maintaining rigorous standards of sensitivity and specificity. In this context, stakeholders across the healthcare spectrum-ranging from hospital networks to academic research institutes-must adapt their operational frameworks to harness next-generation tools and workflows.

Against this backdrop, this executive summary synthesizes critical drivers shaping the diagnostics market, highlights regulatory and policy trends influencing global supply chains, and presents actionable frameworks for segmentation, regional analysis, and competitive positioning. By exploring transformative shifts, tariff impacts, and nuanced market segmentation, readers will gain a holistic perspective on how to navigate the complexities of diagnostic innovation, optimize resource allocation, and deliver improved patient outcomes in an increasingly interconnected healthcare ecosystem.

How Automation, Data Analytics, and Decentralized Testing Models Are Revolutionizing Pathogen Detection and Clinical Decision Pathways

The infectious disease diagnostic sector is being reshaped by a convergence of automation, high-throughput capabilities, and data analytics that enable laboratories to process samples at unprecedented scale. Cutting-edge assays compatible with mass spectrometry and next-generation sequencing are complementing immunoassay and PCR technologies, allowing for multiplexed detection of bacterial, viral, fungal, and parasitic pathogens with remarkable turnaround times.

Meanwhile, the integration of cloud-enabled software platforms has streamlined data aggregation from instruments such as immunoassay analyzers and microarrays, supporting real-time surveillance and predictive modeling of outbreak patterns. This shift toward decentralized testing is further bolstered by advanced portable PCR systems and antigen detection kits, extending diagnostic reach beyond centralized labs into point-of-care settings. Consequently, clinical decision-making pathways are evolving to incorporate telehealth consultations informed by rapid test results, signaling a fundamental transformation in how infectious diseases are identified, monitored, and managed on a global scale.

Navigating New Trade Barriers and Strategic Sourcing Adjustments to Sustain Diagnostic Testing Operations Under Evolving Tariff Regimes

Tariff policies implemented throughout 2025 have introduced new cost considerations for imported reagents, instruments, and key components used in infectious disease testing. Many diagnostic laboratories have encountered increased expenses for antigen detection kits and immunoassay analyzers sourced from affected regions, prompting procurement teams to explore alternative domestic suppliers or adjust testing volumes to mitigate budgetary constraints.

In parallel, reagent and kit manufacturers have responded by diversifying regional manufacturing footprints, establishing production lines for ELISA, immunoassay, and PCR kits in tariff-exempt jurisdictions. Software developers for laboratory information management systems have also recalibrated pricing models to accommodate higher import costs for hardware integrations. Collectively, these measures have fostered a more resilient supply chain, though stakeholders must remain vigilant to potential delays and regulatory changes that could further influence global trade dynamics.

Integrating Product, Sample, Testing, Pathogen, Disease, and End-User Perspectives to Illuminate Tailored Diagnostic Pathways

An effective segmentation approach illuminates the nuanced drivers across product categories, revealing distinct adoption patterns in instruments, reagents and kits, and software solutions. Within instruments, immunoassay analyzers maintain strong clinical demand for routine screenings, while mass spectrometers and microarrays cater to specialized research applications. PCR systems continue to expand their footprint in both centralized laboratories and point-of-care settings. Reagents and kits exhibit diverse usage; antigen detection formats excel in rapid testing scenarios, ELISA and immunoassay kits underpin high-throughput workflows, and PCR kits deliver unmatched sensitivity for molecular diagnostics.

Sample type differentiation underscores the importance of specimen matrix compatibility, with blood derivatives such as plasma, serum, and whole blood dominating hospital-based testing and stool and urine assays facilitating gastrointestinal and urinary pathogen detection. Swab collections, spanning nasal, rectal, and throat formats, are pivotal for respiratory screening programs. Diagnostic methodologies fall broadly into laboratory testing and point-of-care modalities, each aligned with specific clinical contexts and throughput requirements. Pathogen focus spans bacterial, fungal, parasitic, and viral targets; within the viral cohort, hepatitis subtypes, HIV, and influenza command critical surveillance priority. Disease classifications span meningitis and pneumonia to vector-borne infections such as dengue and Zika, informing tailored assay development. Finally, end-user environments ranging from academic institutes to diagnostic laboratories and hospitals guide commercialization strategies and service level agreements for comprehensive diagnostic platforms.

Examining Regional Healthcare Infrastructures and Policy Drivers That Shape Diagnostic Innovation and Adoption Patterns Globally

In the Americas region, mature healthcare infrastructures and robust reimbursement frameworks continue to drive adoption of advanced diagnostic platforms. North America's network of reference laboratories and academic research centers spearheads validation of novel assays, while Latin American markets exhibit growing demand for cost-effective rapid tests amid expanding public health initiatives. Economic diversification and government investments in molecular diagnostics have bolstered capacity for large-scale screening programs.

Europe, Middle East, and Africa present a mosaic of requirements, from stringent regulatory compliance in Western Europe to emerging surveillance needs in the Middle East and resource-constrained settings across Africa. Collaborative efforts among public health agencies have accelerated deployment of point-of-care antigen tests and portable PCR systems during outbreak responses, redefining standard practices for decentralized testing.

Asia-Pacific markets showcase dynamic growth fueled by rising awareness of infectious disease preparedness and expanding digital health ecosystems. Government initiatives in countries such as China and India are catalyzing local manufacturing capabilities for reagents and instruments, while Southeast Asian nations integrate multiplexed assays into national screening programs. Across all regions, the convergence of technology, policy, and infrastructure investments is shaping a more agile and responsive diagnostic landscape.

Exploring Strategic Alliances and Platform Integrations Driving Faster Assay Development and Scalable Diagnostic Solutions

Spotlight on Leading Innovators and Strategic Collaborations Elevating Diagnostic Excellence

A cohort of established instrument manufacturers and emerging reagent developers are forging collaborative alliances to accelerate the translation of research-grade assays into clinical practice. Partnerships between microarray providers and software firms have enabled seamless data interpretation pipelines, while joint ventures between kit manufacturers and reference laboratories ensure rigorous performance validation under diverse clinical conditions.

Key diagnostic companies are investing in modular instrument architectures that support rapid assay deployment, leveraging scalable reagent supply chains to meet fluctuating demand during epidemic surges. Software integrators are enhancing interoperability with electronic health record systems to deliver actionable insights directly to clinicians. Collectively, these strategic initiatives underscore a shared commitment to driving continuous innovation, optimizing operational efficiencies, and strengthening the global diagnostics ecosystem through synergistic partnerships.

Building Resilient Manufacturing, Data-Driven Insights, and Collaborative Networks to Accelerate Diagnostic Agility and Market Response

Executives should prioritize the diversification of manufacturing footprints to mitigate supply chain vulnerabilities and reduce exposure to trade policy fluctuations. By adopting flexible production models for key reagents and instruments, organizations can rapidly scale output in response to local outbreak scenarios. Moreover, investing in modular, software-driven platforms will facilitate the seamless integration of new assay chemistries, shortening time to market for emerging pathogen targets.

Leaders must also foster cross-sector collaborations that bridge academic research, clinical laboratories, and public health agencies, creating feedback loops for continuous assay refinement. Embracing data-driven decision-making frameworks-leveraging predictive analytics from real-world testing data-will empower stakeholders to anticipate shifts in pathogen prevalence and deploy targeted diagnostic interventions. Finally, building comprehensive education programs for end-users can drive proficiency in advanced testing methodologies, ensuring optimal utilization of instruments and reagents across diverse care settings.

Detailing Rigorous Data Gathering, Expert Interviews, and Taxonomy Frameworks That Ensure Objective and Actionable Market Analysis

Our analysis synthesizes primary insights from in-depth interviews with senior executives at diagnostic laboratories, kit manufacturers, software developers, and healthcare policymakers. Secondary research leveraged peer-reviewed journals, regulatory filings, and public health agency reports to validate technology adoption trends and regional deployment patterns. Proprietary frameworks were applied to map product and disease classifications, ensuring a consistent taxonomy across instruments, reagents, sample types, and end-user segments.

Quantitative data was cross-referenced with historical trade and policy databases to assess tariff impacts, while real-world usage statistics were examined to refine segmentation insights. Scenario planning exercises facilitated the evaluation of strategic sourcing options and partnership models. All findings were peer reviewed by subject matter experts to ensure accuracy, relevance, and practical applicability for decision-makers seeking strategic guidance in the dynamic infectious disease diagnostics market.

Reinforcing the Role of Adaptive Technologies and Collaborative Strategies in Shaping the Future of Infectious Disease Detection

As the global healthcare ecosystem continues to confront emerging infectious threats, the ability to rapidly detect and characterize pathogens remains the cornerstone of effective response strategies. Technological advancements in assay modalities, combined with robust software integration and decentralized testing capabilities, are redefining diagnostic workflows and enabling proactive patient management.

By embracing diversified manufacturing, leveraging real-world data analytics, and cultivating strategic partnerships, stakeholders can navigate regulatory and trade complexities while delivering high-impact diagnostic solutions. Ultimately, the organizations that align operational agility with a deep understanding of regional and segment-specific dynamics will secure leadership positions and contribute meaningfully to improved global health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising need for rapid diagnostics for early detection of infectious diseases
  • 5.2. Adoption of AI-driven predictive analytics optimizing outbreak surveillance and response strategies
  • 5.3. Increasing demand for rapid antigen screening in airports and public venues enhancing community safety
  • 5.4. Expansion of point-of-care multiplex assays driving decentralized infectious disease testing accessibility
  • 5.5. Integration of CRISPR-based diagnostics streamlining rapid pathogen detection workflows
  • 5.6. Expansion of telehealth-linked diagnostic platforms accelerating remote infectious disease management
  • 5.7. Advancements in next-generation sequencing enabling comprehensive pathogen identification in clinical labs
  • 5.8. Shift toward at-home molecular testing kits empowering patient-centric infectious disease monitoring
  • 5.9. Genomic tools powering the new era of infection tracking
  • 5.10. Implementation of digital biomarkers and wearable sensors to predict infection onset before symptoms

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Infectious Disease Diagnostic Market, by Product

  • 8.1. Introduction
  • 8.2. Instruments
    • 8.2.1. Immunoassay Analyzers
    • 8.2.2. Mass Spectrometers
    • 8.2.3. Microarrays
    • 8.2.4. PCR Systems
  • 8.3. Reagents & Kits
    • 8.3.1. Antigen Detection Kits
    • 8.3.2. ELISA Kits
    • 8.3.3. Immunoassay Kits
    • 8.3.4. PCR Kits
  • 8.4. Software

9. Infectious Disease Diagnostic Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Blood
    • 9.2.1. Plasma
    • 9.2.2. Serum
    • 9.2.3. Whole Blood
  • 9.3. Stool
  • 9.4. Swab
    • 9.4.1. Nasal
    • 9.4.2. Rectal
    • 9.4.3. Throat
  • 9.5. Urine

10. Infectious Disease Diagnostic Market, by Testing Type

  • 10.1. Introduction
  • 10.2. Laboratory Testing
  • 10.3. PoC Testing

11. Infectious Disease Diagnostic Market, by Pathogen Type

  • 11.1. Introduction
  • 11.2. Bacterial
  • 11.3. Fungal
  • 11.4. Parasitic
  • 11.5. Viral
    • 11.5.1. Hepatitis
    • 11.5.2. HIV
    • 11.5.3. Influenza

12. Infectious Disease Diagnostic Market, by Disease Type

  • 12.1. Introduction
  • 12.2. Bacterial Infectious Diseases
    • 12.2.1. Meningitis
    • 12.2.2. Pneumonia
    • 12.2.3. Tuberculosis
  • 12.3. Fungal Infections
    • 12.3.1. Aspergillosis
    • 12.3.2. Candidiasis
    • 12.3.3. Cryptococcosis
  • 12.4. Parasitic Infections
    • 12.4.1. Leishmaniasis
    • 12.4.2. Malaria
    • 12.4.3. Schistosomiasis
  • 12.5. Vector-borne Infections
    • 12.5.1. Dengue Fever
    • 12.5.2. Lyme Disease
    • 12.5.3. Zika Virus
  • 12.6. Viral Infectious Diseases
    • 12.6.1. Hepatitis (A, B, C)
    • 12.6.3. HIV/AIDS
    • 12.6.4. Influenza

13. Infectious Disease Diagnostic Market, by End-User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutes
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals & Clinics

14. Americas Infectious Disease Diagnostic Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Infectious Disease Diagnostic Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Infectious Disease Diagnostic Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bio-Rad Laboratories, Inc.
    • 17.3.2. F. Hoffmann-La Roche Ltd.
    • 17.3.3. Abbott Laboratories
    • 17.3.4. Adaptive Biotechnologies Corporation
    • 17.3.5. Agilent Technologies, Inc.
    • 17.3.6. Becton, Dickinson and Company
    • 17.3.7. Bio-Techne Corporation
    • 17.3.8. bioMerieux SA
    • 17.3.9. Boston Scientific Corporation
    • 17.3.10. Bruker Corporation
    • 17.3.11. Cardinal Health Inc.
    • 17.3.12. Cook Medical Incorporated
    • 17.3.13. Danaher Corporation
    • 17.3.14. GE HealthCare Technologies Inc.
    • 17.3.15. Grifols, S.A.
    • 17.3.16. Hologic Inc.
    • 17.3.17. Illumina, Inc.
    • 17.3.18. Johnson & Johnson Services Inc.
    • 17.3.19. Konica Minolta, Inc.
    • 17.3.20. Koninklijke Philips N.V.
    • 17.3.21. MedMira Inc.
    • 17.3.22. Medtronic PLC
    • 17.3.23. Merck KGaA
    • 17.3.24. Olympus Corporation
    • 17.3.25. Perkin Elmer, Inc.
    • 17.3.26. Pfizer Inc.
    • 17.3.27. Qiagen N.V.
    • 17.3.28. Quest Diagnostics Incorporated
    • 17.3.29. Siemens Healthineers AG
    • 17.3.30. Sysmex Corporation
    • 17.3.31. Thermo Fisher Scientific, Inc.
    • 17.3.32. Trivitron Healthcare

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASE DIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHAI
  • FIGURE 28. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHSTATISTICS
  • FIGURE 29. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHCONTACTS
  • FIGURE 30. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASE DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ANTIGEN DETECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ANTIGEN DETECTION KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PLASMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SERUM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STOOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STOOL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY THROAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY THROAT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MENINGITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CANDIDIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MALARIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MALARIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DENGUE FEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DENGUE FEVER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LYME DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LYME DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS (A, B, C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS (A, B, C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS B & C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS B & C, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV/AIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 171. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 173. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 175. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 177. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 217. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 219. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 221. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 223. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 227. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 229. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 234. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 235. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 238. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 239. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 241. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 243. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 245. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 247. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 249. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 251. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 253. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 255. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 258. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 259. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 261. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 267. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 271. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 273. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 275. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 277. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 279. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 280. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 281. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 283. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 285. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 287. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 290. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 291. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 293. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 299. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 302. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 303. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 305. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 306. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 307. BRAZIL INFECTIOUS DIS